SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations

Tepotinib is an oral MET inhibitor approved for metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 (METex14) skipping mutations. Examining treatment-naive or tepotinib-resistant cells with MET amplification or METex14 skipping mutations identifies other receptor tyrosine kinases (RT...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:iScience
मुख्य लेखकों: Pudelko, Linda, Jaehrling, Frank, Reusch, Christof, Vitri, Sanziago, Stroh, Christopher, Linde, Nina, Sanderson, Michael P., Musch, Doreen, Lebrun, Catherine Jorand, Keil, Marina, Esdar, Christina, Blaukat, Andree, Rosell, Rafael, Schumacher, Karl Maria, Karachaliou, Niki
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Elsevier 2020
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7718487/
https://ncbi.nlm.nih.gov/pubmed/33305187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.isci.2020.101832
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन